UroGen Pharma Ltd. Logo

UroGen Pharma Ltd.

Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.

URGN | US

Overview

Corporate Details

ISIN(s):
IL0011407140
LEI:
Country:
United States of America
Address:
9 HA'TA'ASIYA ST, 4365007 RA'ANANA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

UroGen Pharma Ltd. is a biotechnology company dedicated to developing and commercializing innovative solutions for urothelial and other specialty cancers. The company focuses on creating transformative, non-surgical therapies for urological diseases. Its lead commercial product, ZUSDURI™, is an FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UroGen utilizes its proprietary RTGel™ reverse-thermal hydrogel technology to enable sustained local delivery of therapeutic agents, aiming to improve patient outcomes and revolutionize the treatment paradigm in uro-oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all UroGen Pharma Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for UroGen Pharma Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for UroGen Pharma Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ectin Research AB Logo
Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.
Sweden
ECTIN B
Edesa Biotech, Inc. Logo
Develops treatments for inflammatory and immune diseases like Acute Respiratory Distress Syndrome.
United States of America
EDSA
Edgewise Therapeutics, Inc. Logo
Developing novel therapeutics for rare and serious muscle disorders.
United States of America
EWTX
Editas Medicine, Inc. Logo
Developing CRISPR-based genomic medicines to treat serious and rare genetic diseases.
United States of America
EDIT
Eevia Health Plc Logo
Manufactures validated polyphenol extracts from Arctic plants for the supplement & food industries.
Finland
EEVIA
Egetis Therapeutics Logo
Develops and commercializes drugs for serious rare diseases with unmet medical needs.
Sweden
EGTX
EIKEN CHEMICAL CO.,LTD. Logo
Manufacturer of clinical diagnostics, specializing in FIT systems for cancer and microbiological tests.
Japan
4549
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan
4523
Elanco Animal Health Inc Logo
Develops medicines, vaccines, and services to treat and prevent disease in pets and farm animals.
United States of America
ELAN
Eledon Pharmaceuticals, Inc. Logo
Develops immunomodulatory therapies to prevent organ rejection in transplant patients.
United States of America
ELDN

Talk to a Data Expert

Have a question? We'll get back to you promptly.